CA3029654A1 - Composes d'amino acides de copolymeres et leurs applications - Google Patents
Composes d'amino acides de copolymeres et leurs applications Download PDFInfo
- Publication number
- CA3029654A1 CA3029654A1 CA3029654A CA3029654A CA3029654A1 CA 3029654 A1 CA3029654 A1 CA 3029654A1 CA 3029654 A CA3029654 A CA 3029654A CA 3029654 A CA3029654 A CA 3029654A CA 3029654 A1 CA3029654 A1 CA 3029654A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amino acid
- polypeptides
- amino acids
- rcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 726
- 229920001577 copolymer Polymers 0.000 title abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 814
- 150000001413 amino acids Chemical class 0.000 claims abstract description 666
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 575
- 229920001184 polypeptide Polymers 0.000 claims abstract description 551
- 239000000427 antigen Substances 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 96
- 102000036639 antigens Human genes 0.000 claims abstract description 96
- 230000000890 antigenic effect Effects 0.000 claims abstract description 90
- 229920005604 random copolymer Polymers 0.000 claims abstract description 75
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 235000001014 amino acid Nutrition 0.000 claims description 824
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 173
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 81
- 235000018102 proteins Nutrition 0.000 claims description 80
- 235000004279 alanine Nutrition 0.000 claims description 74
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 73
- 238000009826 distribution Methods 0.000 claims description 68
- 238000006467 substitution reaction Methods 0.000 claims description 68
- 201000010099 disease Diseases 0.000 claims description 64
- 102000013498 tau Proteins Human genes 0.000 claims description 63
- 108010026424 tau Proteins Proteins 0.000 claims description 63
- 239000004475 Arginine Substances 0.000 claims description 61
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 61
- 235000009697 arginine Nutrition 0.000 claims description 61
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 55
- 239000004472 Lysine Substances 0.000 claims description 55
- 235000018977 lysine Nutrition 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 53
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 34
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 31
- 230000006052 T cell proliferation Effects 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 29
- 210000001616 monocyte Anatomy 0.000 claims description 28
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 26
- 235000013922 glutamic acid Nutrition 0.000 claims description 26
- 239000004220 glutamic acid Substances 0.000 claims description 26
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 24
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 235000003704 aspartic acid Nutrition 0.000 claims description 24
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 108010080146 androgen receptors Proteins 0.000 claims description 22
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 21
- 206010002022 amyloidosis Diseases 0.000 claims description 21
- 230000001717 pathogenic effect Effects 0.000 claims description 21
- 210000004899 c-terminal region Anatomy 0.000 claims description 20
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 17
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 17
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 17
- 235000008729 phenylalanine Nutrition 0.000 claims description 17
- 230000026731 phosphorylation Effects 0.000 claims description 17
- 238000006366 phosphorylation reaction Methods 0.000 claims description 17
- 208000018737 Parkinson disease Diseases 0.000 claims description 16
- 102000019034 Chemokines Human genes 0.000 claims description 14
- 108010012236 Chemokines Proteins 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 14
- 230000001575 pathological effect Effects 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 108091000054 Prion Proteins 0.000 claims description 12
- 102000029797 Prion Human genes 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 102100032187 Androgen receptor Human genes 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 10
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 9
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 9
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 9
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 208000017004 dementia pugilistica Diseases 0.000 claims description 9
- 102000004321 Atrophin-1 Human genes 0.000 claims description 8
- 108090000806 Atrophin-1 Proteins 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 241000701806 Human papillomavirus Species 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 7
- 208000018282 ACys amyloidosis Diseases 0.000 claims description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 102000004407 Lactalbumin Human genes 0.000 claims description 5
- 108050004114 Monellin Proteins 0.000 claims description 5
- 108010071690 Prealbumin Proteins 0.000 claims description 5
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 5
- 101710190759 Serum amyloid A protein Proteins 0.000 claims description 5
- 102000009190 Transthyretin Human genes 0.000 claims description 5
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 5
- 102000007372 Ataxin-1 Human genes 0.000 claims description 4
- 108010032963 Ataxin-1 Proteins 0.000 claims description 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 102000015833 Cystatin Human genes 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 102000004878 Gelsolin Human genes 0.000 claims description 4
- 108090001064 Gelsolin Proteins 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108090000942 Lactalbumin Proteins 0.000 claims description 4
- 102100033468 Lysozyme C Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 102100037925 Prothymosin alpha Human genes 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 108050004038 cystatin Proteins 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 108010014750 prothymosin alpha Proteins 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 208000023769 AA amyloidosis Diseases 0.000 claims description 3
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 3
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims description 3
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims description 3
- 102000014461 Ataxins Human genes 0.000 claims description 3
- 108010078286 Ataxins Proteins 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims description 3
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 3
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 3
- 201000007888 Finnish type amyloidosis Diseases 0.000 claims description 3
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 3
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims description 3
- 208000032838 Hereditary amyloidosis with primary renal involvement Diseases 0.000 claims description 3
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims description 3
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 3
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 3
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022435 Light chain deposition disease Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 3
- 201000007891 familial visceral amyloidosis Diseases 0.000 claims description 3
- 201000006061 fatal familial insomnia Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 210000004153 islets of langerhan Anatomy 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 206010023497 kuru Diseases 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 208000021629 neuronal intranuclear inclusion disease Diseases 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 3
- 208000008864 scrapie Diseases 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 3
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000589562 Brucella Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241001445332 Coxiella <snail> Species 0.000 claims description 2
- 241000589601 Francisella Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 241000186781 Listeria Species 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 241000187654 Nocardia Species 0.000 claims description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 2
- 241000606701 Rickettsia Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000001307 androgen receptors Human genes 0.000 claims 14
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 229940024606 amino acid Drugs 0.000 description 567
- 230000000875 corresponding effect Effects 0.000 description 76
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 39
- 239000002245 particle Substances 0.000 description 26
- 239000004626 polylactic acid Substances 0.000 description 25
- 229920000747 poly(lactic acid) Polymers 0.000 description 24
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 19
- 238000013461 design Methods 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000007170 pathology Effects 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000035557 fibrillogenesis Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000010647 peptide synthesis reaction Methods 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 101001071233 Homo sapiens PHD finger protein 1 Proteins 0.000 description 7
- 102100036879 PHD finger protein 1 Human genes 0.000 description 7
- 208000034799 Tauopathies Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 210000001202 rhombencephalon Anatomy 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 239000000816 peptidomimetic Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010072051 Glatiramer Acetate Proteins 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 229940038717 copaxone Drugs 0.000 description 4
- 230000002518 glial effect Effects 0.000 description 4
- 230000006951 hyperphosphorylation Effects 0.000 description 4
- 230000001024 immunotherapeutic effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 210000004558 lewy body Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000006396 nitration reaction Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 3
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 108010001441 Phosphopeptides Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- -1 myristoylation) Chemical class 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- OEBXWWBYZJNKRK-UHFFFAOYSA-N 1-methyl-2,3,4,6,7,8-hexahydropyrimido[1,2-a]pyrimidine Chemical compound C1CCN=C2N(C)CCCN21 OEBXWWBYZJNKRK-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical compound NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-VKHMYHEASA-N 3-cyano-L-alanine Chemical compound OC(=O)[C@@H](N)CC#N BXRLWGXPSRYJDZ-VKHMYHEASA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101001071234 Arabidopsis thaliana SEC12-like protein 1 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000043334 C9orf72 Human genes 0.000 description 1
- 108700030955 C9orf72 Proteins 0.000 description 1
- 101150014718 C9orf72 gene Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102100020720 Calcium channel flower homolog Human genes 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016202 Familial Amyloidosis Diseases 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 102100028953 Gelsolin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
- 101000932468 Homo sapiens Calcium channel flower homolog Proteins 0.000 description 1
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 description 1
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- JMQMNWIBUCGUDO-UHFFFAOYSA-N L-Djenkolic acid Natural products OC(=O)C(N)CSCSCC(N)C(O)=O JMQMNWIBUCGUDO-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- JMQMNWIBUCGUDO-WHFBIAKZSA-N L-djenkolic acid Chemical compound OC(=O)[C@@H](N)CSCSC[C@H](N)C(O)=O JMQMNWIBUCGUDO-WHFBIAKZSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100366159 Mus musculus Sod1 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 108700013394 SOD1 G93A Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000036278 TDP-43 proteinopathy Diseases 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006329 citrullination Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 101150081397 dps gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000005649 gangliocytoma Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000017105 hereditary amyloidosis Diseases 0.000 description 1
- 102000056070 human SOD1 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 210000002511 neuropil thread Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102200028488 rs782308462 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357800P | 2016-07-01 | 2016-07-01 | |
| US62/357,800 | 2016-07-01 | ||
| US201762478410P | 2017-03-29 | 2017-03-29 | |
| US62/478,410 | 2017-03-29 | ||
| PCT/US2017/040598 WO2018006092A1 (fr) | 2016-07-01 | 2017-07-03 | Composés d'amino acides de copolymères et leurs applications. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3029654A1 true CA3029654A1 (fr) | 2018-01-04 |
Family
ID=60787458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3029654A Abandoned CA3029654A1 (fr) | 2016-07-01 | 2017-07-03 | Composes d'amino acides de copolymeres et leurs applications |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3478316A1 (fr) |
| AU (1) | AU2017290907A1 (fr) |
| CA (1) | CA3029654A1 (fr) |
| WO (1) | WO2018006092A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| JP7181994B2 (ja) * | 2018-09-05 | 2022-12-01 | シーメンス エナジー グローバル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | 回転防止特徴を有する非接触シール |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0401863A3 (en) * | 2001-10-03 | 2012-09-28 | Harvard College | Amino acid-copolymers for suppression of autoimmune diseases, and methods of use |
| EP1750742A2 (fr) * | 2004-05-07 | 2007-02-14 | Peptimmune, Inc. | Methodes de traitement de maladie a l'aide de copolymeres aleatoires |
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| WO2006031727A2 (fr) * | 2004-09-13 | 2006-03-23 | President And Fellows Of Harvard College | Peptides destines au traitement de maladies auto-immunes |
| WO2009075854A2 (fr) * | 2007-12-10 | 2009-06-18 | Peptimmune Inc. | Quantification efficace de mélanges de peptides complexes dans des échantillons de tissus et procédés thérapeutiques améliorés |
| CA2759118A1 (fr) * | 2008-04-17 | 2009-10-22 | Declion Pharmaceuticals, Inc. | Conception et synthese de compositions de polymeres sequences dirigees et leurs anticorps pour le traitement de troubles conformationnels des proteines |
| US20120237472A1 (en) * | 2009-07-24 | 2012-09-20 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
| WO2012150495A1 (fr) * | 2011-05-05 | 2012-11-08 | National Institute Of Immunology | Peptides synthétiques et copolymères aléatoires pour le traitement de troubles auto-immuns |
-
2017
- 2017-07-03 WO PCT/US2017/040598 patent/WO2018006092A1/fr unknown
- 2017-07-03 AU AU2017290907A patent/AU2017290907A1/en not_active Abandoned
- 2017-07-03 EP EP17821442.5A patent/EP3478316A1/fr not_active Withdrawn
- 2017-07-03 CA CA3029654A patent/CA3029654A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018006092A1 (fr) | 2018-01-04 |
| AU2017290907A1 (en) | 2019-02-14 |
| EP3478316A1 (fr) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2968485B1 (fr) | Vaccin peptidique pour la prévention et l'immunothérapie de la démence du type alzheimer | |
| EP1910829B1 (fr) | Prevention et traitement d'une maladie synucleinopathique et amyloidogenique | |
| CA2729414C (fr) | Vaccin contre un intermediaire de repliement des amyloides | |
| KR20100123705A (ko) | 신경퇴행성 장애의 치료를 위한 알파-시뉴클레인의 미모토프 및 이의 백신 | |
| WO2010011999A2 (fr) | Procédés et compositions pour susciter une réponse immunitaire sélective envers les amyloïdes | |
| TW202208409A (zh) | 用於治療阿茲海默症之多抗原決定基疫苗 | |
| WO2010003691A2 (fr) | Bioconjugués comprenant des déterminants antigéniques spécifiques d'auto-anticorps dirigés contre le peptide β-amyloïde utilisables pour une immunothérapie active, ainsi que pour le diagnostic de la maladie d'alzheimer | |
| KR20110071117A (ko) | 변성된 아밀로이드 베타 펩티드 | |
| JP5709876B2 (ja) | 多発性硬化症治療用組成物 | |
| JPH09502346A (ja) | 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用 | |
| CA3029654A1 (fr) | Composes d'amino acides de copolymeres et leurs applications | |
| WO2009054537A1 (fr) | VACCIN PEPTIDIQUE METTANT EN ŒUVRE UNE MOLÉCULE MIMÉTIQUE DE PEPTIDE β- AMYLOÏDE | |
| WO2022031342A1 (fr) | Vaccins anti-tau pour le traitement de la maladie d'alzheimer | |
| EP2106802A1 (fr) | Peptides modifiés en tant que vaccins synthétiques dans une maladie associée à l'amyloïde | |
| US8188046B2 (en) | Amyloid beta peptides and methods of use | |
| US20220023401A1 (en) | Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type | |
| Rossi et al. | Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified β-amyloid peptides | |
| RU2811687C2 (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| EP4103582A1 (fr) | Immunogènes peptidiques ciblant un polypeptide amyloïde d'îlots (iapp) pour la prévention et le traitement de troubles liés à un iapp agrégé |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200831 |